Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281711 | 0.85 | CNR2 (0.35) | HTR2CSLC6A4HTR2ASGMS2CNR2 | |
| SCHEMBL11535532 | 0.66 | MAOA (0.34) | SMN1; SMN2 | |
| SCHEMBL11243618 | 0.65 | LMNA (0.32) | SMN1; SMN2 | |
| SCHEMBL30929883 | 0.60 | CYP4F2 (0.34) | — | |
| SCHEMBL4480785 | 0.60 | EPHX2 (0.49) | SGMS2CNR2CNR1KMT2AMEN1 | |
| SCHEMBL2659786 | 0.59 | EPHX1 (0.42) | SGMS2CNR2CNR1KMT2AMEN1 | |
| SCHEMBL2660289 | 0.59 | EPHX1 (0.42) | SGMS2CNR2CNR1KMT2AMEN1 | |
| SCHEMBL3411535 | 0.58 | KMT2A (0.47) | SGMS2CNR2CNR1KMT2AMEN1 | |
| SCHEMBL638679 | 0.58 | MAOA (0.35) | — | |
| SCHEMBL29405106 | 0.58 | ATP4A (0.35) | HTR2CSLC6A4HTR2AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849642-B2 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH (DE) | 2005-02-01 | — | — | US | disclosed |
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | GRUENENTHAL GMBH. | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183327-A1 | Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring | OPRK1, GRIN3A, OPRM1 | HTR2C 145/4885SLC6A4 175/4885HTR2A 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.